Deal Tracker · Years

Emerging-market pharma deals in 2026

193 pharma deals announced in 2026 across GCC, MENA, Latin America & Southeast Asia, tracked by EPT — licensing, distribution & localization. Most active: ADCAN Pharma, Mubadala Bio, SPIMACO & Arcera Life Sciences. Latest: Laboratorios Siegfried → Laboratorio Chile (M&A / Acquisition, 19 Nov 2026).

193
deals tracked
65
countries involved
$2.7bn
disclosed value (34 deals)
21%
licensing, the top deal type
  • EPT has tracked 193 emerging-market pharma deals in 2026.
  • The most common structures are licensing (21%), distribution (19%) & partnerships (15%).
  • The countries that appear most often are UAE (53), Saudi Arabia (48), United States (24) & Egypt (20).
  • Values were disclosed for 34 of 193 deals, totalling $2.7bn; the largest is DKSH → NewBridge Pharmaceuticals ($390m, 19 Oct 2026).
  • The most active companies: ADCAN Pharma (13), Mubadala Bio (8), SPIMACO (6) & Arcera Life Sciences (5).

Most active companies

ADCAN Pharma (13) · Mubadala Bio (8) · SPIMACO (6) · Arcera Life Sciences (5) · Avalon Pharma (5) · Jamjoom Pharma (5)

Countries involved

UAE (53) · Saudi Arabia (48) · United States (24) · Egypt (20) · China (18) · Switzerland (17)

Largest disclosed deals

Questions

How many emerging-market pharma deals in 2026 has EPT tracked?
193 as of 19 Nov 2026. The most recent is Laboratorios Siegfried → Laboratorio Chile (M&A / Acquisition, 19 Nov 2026).
What types of emerging-market pharma deals in 2026 are most common?
Licensing: 41 (21%); Distribution: 37 (19%); Partnership / Collaboration: 29 (15%); Technology transfer / Localization: 29 (15%).
Which companies are most active in emerging-market pharma deals in 2026?
ADCAN Pharma (13 deals), Mubadala Bio (8 deals), SPIMACO (6 deals), Arcera Life Sciences (5 deals), Avalon Pharma (5 deals), Jamjoom Pharma (5 deals).
What is the largest disclosed emerging-market pharma deal in 2026?
DKSH → NewBridge Pharmaceuticals: $390m (M&A / Acquisition, 19 Oct 2026); Natco Pharma → Adcock Ingram: $260m (Equity / Investment, 8 Jul 2026); Ocugen → Roots Pharmaceutical: $259m (Licensing, 14 Oct 2026). Values are as announced by the parties.
Which countries appear most in emerging-market pharma deals in 2026?
UAE (53), Saudi Arabia (48), United States (24), Egypt (20), China (18), Switzerland (17) — counting where the parties are based and the markets the deals cover.

Browse deals

By region

GCC (83) · MENA (66) · Africa (17) · Latin America (17) · Southeast Asia (17) · Global (LMICs) (14) · CIS & Central Asia (13) · Türkiye (5) · Global ex-US (1)

By country

Saudi Arabia (69) · UAE (61) · China (31) · Egypt (27) · United States (26) · Oman (20) · India (19) · Switzerland (18) · Jordan (14) · South Korea (14) · Kazakhstan (13) · Algeria (12) · Türkiye (12) · United Kingdom (11) · Brazil (10) · Kuwait (10) · Iraq (8) · Morocco (8) · Bahrain (7) · Malaysia (7) · Spain (7) · Argentina (6) · Germany (6) · Indonesia (6) · Philippines (6) · Qatar (6) · Italy (5) · Mexico (5) · Vietnam (5) · France (4) · Taiwan (4) · Tunisia (4) · Canada (3) · Chile (3) · Denmark (3) · Greece (3) · Japan (3) · Lebanon (3) · Nigeria (3) · Pakistan (3) · South Africa (3) · Sweden (3) · Thailand (3) · Azerbaijan (2) · Colombia (2) · Ireland (2) · Kenya (2) · Libya (2) · Netherlands (2) · Singapore (2) · Uruguay (2) · Uzbekistan (2)

By year

2025 (27) · 2024 (6) · 2022 (3) · 2021 (2)

By therapeutic area

Multi-therapy (64) · Oncology (30) · Metabolic / Diabetes (27) · Cardiovascular (17) · Vaccines (15) · Immunology / Inflammation (13) · Rare / Orphan (9) · Infectious Disease (8) · CNS / Neurology (6) · Ophthalmology (6) · Consumer health (5) · Women's Health (4) · Respiratory (2)